{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:28:23Z","timestamp":1789597703019,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T00:00:00Z","timestamp":1655078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s40273-022-01145-7","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T05:02:43Z","timestamp":1655096563000},"page":"777-790","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective"],"prefix":"10.1007","volume":"40","clinical-trial-number":[{"clinical-trial-number":"nct02993523","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1284-8266","authenticated-orcid":false,"given":"Keith W.","family":"Pratz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinglei","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jipan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Montez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Iantuono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Downs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esprit","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,13]]},"reference":[{"issue":"10147","key":"1145_CR1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392(10147):593\u2013606.","journal-title":"Lancet"},{"key":"1145_CR2","unstructured":"Surveillance Epidemiology and End Results (SEER) Program. Cancer stat facts: leukemia\u2014acute myeloid leukemia (AML). 2021 [cited 2021 August 13]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."},{"issue":"1","key":"1145_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40364-020-00196-2","volume":"8","author":"J Yu","year":"2020","unstructured":"Yu J, Jiang PYZ, Sun H, Zhang X, Jiang Z, Li Y, et al. Advances in targeted therapy for acute myeloid leukemia. Biomark Res. 2020;8(1):17.","journal-title":"Biomark Res."},{"key":"1145_CR4","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Guideline Acute Myeloid Leukemia V.2.2021. \u00a9 National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed August 14, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"issue":"15","key":"1145_CR5","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1182\/bloodadvances.2020001920","volume":"4","author":"MA Sekeres","year":"2020","unstructured":"Sekeres MA, Guyatt G, Abel G, Alibhai S, Altman JK, Buckstein R, et al. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2020;4(15):3528\u201349.","journal-title":"Blood Adv"},{"issue":"6","key":"1145_CR6","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1002\/cam4.321","volume":"3","author":"SK Sadashiv","year":"2014","unstructured":"Sadashiv SK, Hilton C, Khan C, Rossetti JM, Benjamin HL, Fazal S, et al. Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia. Cancer Med. 2014;3(6):1570\u20138.","journal-title":"Cancer Med"},{"issue":"3","key":"1145_CR7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291\u20139.","journal-title":"Blood"},{"issue":"1","key":"1145_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3109\/10428194.2011.606382","volume":"53","author":"HK Al-Ali","year":"2012","unstructured":"Al-Ali HK, Jaekel N, Junghanss C, Maschmeyer G, Krahl R, Cross M, et al. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I\/II study. Leuk Lymphoma. 2012;53(1):110\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"1145_CR9","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","volume":"28","author":"AF Cashen","year":"2010","unstructured":"Cashen AF, Schiller GJ, O\u2019Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010;28(4):556\u201361.","journal-title":"J Clin Oncol"},{"issue":"21","key":"1145_CR10","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670\u20137.","journal-title":"J Clin Oncol"},{"key":"1145_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106339","volume":"91","author":"EA Griffiths","year":"2020","unstructured":"Griffiths EA, Carraway HE, Chandhok NS, Prebet T. Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia. Leuk Res. 2020;91:106339.","journal-title":"Leuk Res"},{"issue":"10","key":"1145_CR12","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1182\/bloodadvances.2020001779","volume":"4","author":"AM Zeidan","year":"2020","unstructured":"Zeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, et al. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Adv. 2020;4(10):2192\u2013201.","journal-title":"Blood Adv"},{"issue":"1","key":"1145_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/hematology.2020000154","volume":"2020","author":"AW Roberts","year":"2020","unstructured":"Roberts AW. Therapeutic development and current uses of BCL-2 inhibition. Hematology. 2020;2020(1):1\u20139.","journal-title":"Hematology"},{"key":"1145_CR14","unstructured":"United States Food and Drug Administration. FDA grants regular approval to venetoclax in combination for untreated acute myeloid leukemia. 2020 [cited 2021 August 14]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-venetoclax-combination-untreated-acute-myeloid-leukemia."},{"issue":"7","key":"1145_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"issue":"4","key":"1145_CR16","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1182\/bloodadvances.2020003902","volume":"5","author":"KK Patel","year":"2021","unstructured":"Patel KK, Zeidan AM, Shallis RM, Prebet T, Podoltsev N, Huntington SF. Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. Blood Adv. 2021;5(4):994\u20131002.","journal-title":"Blood Adv"},{"key":"1145_CR17","unstructured":"National Institute for Health and Care Excellence (NICE). Gemtuzumab ozogamicin for untreated acute myeloid leukaemia [ID982]: Committee papers. 2018 [cited 2021 September 20]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta545\/evidence\/appraisal-consultation-committee-papers-pdf-6596279678."},{"key":"1145_CR18","unstructured":"National Institute for Health and Care Excellence (NICE). Midostaurin for untreated acute myeloid leukaemia [TA523]. 2017 [cited 2021 September 20]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta523\/documents\/committee-papers-2."},{"key":"1145_CR19","unstructured":"National Institute for Health and Care Excellence (NICE). Gilteritinib for treating relapsed or refractory acute myeloid leukaemia [TA642]. 2019 [cited 2021 September 20]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta642\/documents\/committee-papers."},{"key":"1145_CR20","unstructured":"Arias E, Bastian B, Xu J, Tejada-Vera B. US state life tables, 2018. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System. 2021;70(1):1\u201318."},{"issue":"5","key":"1145_CR21","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3109\/10428191003661852","volume":"51","author":"D Verma","year":"2010","unstructured":"Verma D, Kantarjian H, Faderl S, O\u2019Brien S, Pierce S, Vu K, et al. Late relapses in acute myeloid leukemia: analysis of characteristics and outcome. Leuk Lymphoma. 2010;51(5):778\u201382.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"1145_CR22","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3727\/096504020X15965357399750","volume":"28","author":"A Patel","year":"2021","unstructured":"Patel A, Agha M, Raptis A, Hou J-Z, Farah R, Redner RL, et al. Outcomes of patients with acute myeloid leukemia who relapse after 5 years of complete remission. Oncol Res. 2021;28(7):811\u20134.","journal-title":"Oncol Res"},{"issue":"1","key":"1145_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/10428190601043252","volume":"48","author":"BC Medeiros","year":"2007","unstructured":"Medeiros BC, Minden MD, Schuh AC, Schimmer AD, Yee K, Lipton JH, et al. Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (>5 years). Leuk Lymphoma. 2007;48(1):65\u201371.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"1145_CR24","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708\u201315.","journal-title":"Value Health."},{"key":"1145_CR25","unstructured":"Wehler E, Storm M, Kowal S, Campbell C, Boscoe A. A health state utility model estimating the impact of ivosidenib on quality of life in patients with relapsed\/refractory acute myeloid leukemia. Presented at the 23rd Congress of the European Hematology Association meeting during June 14\u201317, 2018 in Stockholm, Sweden. 2018. Available from: https:\/\/investor.agios.com\/static-files\/25de7161-9a10-4d8c-8a03-8bd5e7d0a5d3. Accessed 3 May 2022."},{"issue":"25","key":"1145_CR26","doi-asserted-by":"publisher","first-page":"4116","DOI":"10.1200\/JCO.2006.07.0409","volume":"24","author":"BA Guadagnolo","year":"2006","unstructured":"Guadagnolo BA, Punglia RS, Kuntz KM, Mauch PM, Ng AK. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin\u2019s disease. J Clin Oncol. 2006;24(25):4116\u201322.","journal-title":"J Clin Oncol"},{"key":"1145_CR27","unstructured":"United States Bureau of Economic Analysis. Price indexes for personal consumption expenditures by major type of product. Personal Consumption Expenditure (PCE) Price Index, health care. 2021 [cited 2021 May 1]. Available from: https:\/\/apps.bea.gov\/iTable\/iTable.cfm?reqid=19&step=2#reqid=19&step=2&isuri=1&1921=survey."},{"key":"1145_CR28","unstructured":"IBM Micromedex. RED BOOK Online. 2021 [cited 2021 April 27]. Available from: https:\/\/www.micromedexsolutions.com."},{"key":"1145_CR29","unstructured":"Centers for Medicare and Medicaid Services. Medicare Physician Fee Schedule. 2020 [cited 2021 April 29]. Available from: https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search."},{"issue":"2","key":"1145_CR30","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.26039","volume":"96","author":"DA Pollyea","year":"2021","unstructured":"Pollyea DA, Pratz K, Letai A, Jonas BA, Wei AH, Pullarkat V, et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study. Am J Hematol. 2021;96(2):208\u201317.","journal-title":"Am J Hematol"},{"key":"1145_CR31","unstructured":"Healthcare Cost and Utilization Project. 2016 Hospital inpatient national statistics. 2018 [cited 2020 June 20]. Available from: https:\/\/hcupnet.ahrq.gov\/#setup."},{"issue":"1","key":"1145_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7\u201317.","journal-title":"Blood"},{"issue":"8","key":"1145_CR33","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1182\/bloodadvances.2018016121","volume":"2","author":"M Stahl","year":"2018","unstructured":"Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, et al. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Adv. 2018;2(8):923\u201332.","journal-title":"Blood Adv"},{"issue":"4","key":"1145_CR34","doi-asserted-by":"publisher","first-page":"pkz048","DOI":"10.1093\/jncics\/pkz048","volume":"3","author":"L-W Mau","year":"2019","unstructured":"Mau L-W, Meyer C, Burns LJ, Saber W, Steinert P, Vanness DJ, et al. Reimbursement, utilization, and 1-year survival post-allogeneic transplantation for Medicare beneficiaries with acute myeloid leukemia. JNCI Cancer Spectr. 2019;3(4):pkz048.","journal-title":"JNCI Cancer Spectr."},{"key":"1145_CR35","unstructured":"United States Food and Drug Administration. Highlights of prescribing information: VENCLEXTA (venetoclax). 2020 [cited 2021 April 29]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208573s023lbl.pdf."},{"key":"1145_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.leukres.2018.06.010","volume":"71","author":"JA Bell","year":"2018","unstructured":"Bell JA, Galaznik A, Farrelly E, Blazer M, Murty S, Ogbonnaya A, et al. Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States. Leuk Res. 2018;71:27\u201333.","journal-title":"Leuk Res"},{"issue":"11","key":"1145_CR37","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1080\/13696998.2018.1513847","volume":"21","author":"M Hagiwara","year":"2018","unstructured":"Hagiwara M, Sharma A, Chung KC, Delea TE. Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia. J Med Econ. 2018;21(11):1119\u201330.","journal-title":"J Med Econ"},{"issue":"2","key":"1145_CR38","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bbmt.2007.10.010","volume":"14","author":"AM Saito","year":"2008","unstructured":"Saito AM, Cutler C, Zahrieh D, Soiffer RJ, Ho VT, Alyea EP, et al. Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant. 2008;14(2):197\u2013207.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1145_CR39","unstructured":"American Association of Blood Banks (AABB). Centers for Medicare and Medicaid Services proposes Medicare hospital outpatient payment rates and policies for CY 2021. 2020 [cited 2021 April 29]. Available from: https:\/\/www.aabb.org\/docs\/default-source\/default-document-library\/positions\/opps-2021-final-rule-summary.pdf?sfvrsn=fcc7f4c2_4."},{"key":"1145_CR40","unstructured":"National Institute for Health and Care Excellence (NICE). Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts: Committee papers. 2016 [cited 2021 April 29]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta399\/documents\/committee-papers."},{"key":"1145_CR41","unstructured":"Centers for Medicare and Medicaid Services. Clinical Laboratory Fee Schedule Files. 2020 [cited 2021 May 14]. Available from: https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/ClinicalLabFeeSched\/Clinical-Laboratory-Fee-Schedule-Files.  Accessed 3 May 2022."},{"issue":"6","key":"1145_CR42","doi-asserted-by":"publisher","first-page":"75s","DOI":"10.1200\/JOP.2011.000469","volume":"8","author":"B Chastek","year":"2012","unstructured":"Chastek B, Harley C, Kallich J, Newcomer L, Paoli CJ, Teitelbaum AH. Health care costs for patients with cancer at the end of life. J Oncol Pract. 2012;8(6):75s\u201380s.","journal-title":"J Oncol Pract"},{"key":"1145_CR43","unstructured":"Institute for Clinical and Economic Review (ICER). 2020\u20132023 Value Assessment Framework. 2020 [cited 2021 September 20]. Available from: https:\/\/icer.org\/wp-content\/uploads\/2021\/03\/ICER_2020_2023_VAF_013120-4-2.pdf.  Accessed 3 May 2022."},{"issue":"8","key":"1145_CR44","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.clinthera.2021.06.011","volume":"43","author":"CZ Qi","year":"2021","unstructured":"Qi CZ, Bollu V, Yang H, Dalal A, Zhang S, Zhang J. Cost-effectiveness analysis of tisagenlecleucel for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma in the United States. Clin Ther. 2021;43(8):1300\u201319.","journal-title":"Clin Ther"},{"issue":"1","key":"1145_CR45","doi-asserted-by":"publisher","first-page":"10838","DOI":"10.1038\/s41598-021-90405-1","volume":"11","author":"J Salcedo","year":"2021","unstructured":"Salcedo J, Bulovic J, Young CM. Cost-effectiveness of a hypothetical cell or gene therapy cure for sickle cell disease. Sci Rep. 2021;11(1):10838.","journal-title":"Sci Rep"},{"issue":"1","key":"1145_CR46","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13023-018-0914-3","volume":"13","author":"D Sharma","year":"2018","unstructured":"Sharma D, Xing S, Hung Y-T, Caskey RN, Dowell ML, Touchette DR. Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States. Orphanet J Rare Dis. 2018;13(1):172.","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"1145_CR47","first-page":"1089","volume":"25","author":"QA Le","year":"2019","unstructured":"Le QA. Patient-level modeling approach using discrete-event simulation: a cost-effectiveness study of current treatment guidelines for women with postmenopausal osteoporosis. J Manag Care Spec Pharm. 2019;25(10):1089\u201395.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"1145_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002532","volume":"15","author":"E Lin","year":"2018","unstructured":"Lin E, Chertow GM, Yan B, Malcolm E, Goldhaber-Fiebert JD. Cost-effectiveness of multidisciplinary care in mild to moderate chronic kidney disease in the United States: a modeling study. PLOS Med. 2018;15(3): e1002532.","journal-title":"PLOS Med"},{"issue":"8","key":"1145_CR49","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.37765\/ajmc.2021.88726","volume":"27","author":"MA Chaudhary","year":"2021","unstructured":"Chaudhary MA, Lubinga SJ, Smare C, Hertel N, Penrod JR. Cost-effectiveness of nivolumab in patients with NSCLC in the United States. Am J Manag Care. 2021;27(8):e254\u201360.","journal-title":"Am J Manag Care"},{"issue":"12","key":"1145_CR50","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.3324\/haematol.2012.066100","volume":"97","author":"B Oran","year":"2012","unstructured":"Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97(12):1916\u201324.","journal-title":"Haematologica"},{"issue":"7","key":"1145_CR51","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1182\/blood.2019002140","volume":"135","author":"GJ Roboz","year":"2020","unstructured":"Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020;135(7):463\u201371.","journal-title":"Blood"},{"key":"1145_CR52","unstructured":"National Institute for Health and Care Excellence (NICE). Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts. Technology appraisal guidance [TA399]. 2016 [cited 2021 September 20]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta399."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01145-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-022-01145-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01145-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T18:18:36Z","timestamp":1658341116000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-022-01145-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,13]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1145"],"URL":"https:\/\/doi.org\/10.1007\/s40273-022-01145-7","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,13]]},"assertion":[{"value":"7 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Support for this study was provided by Genentech, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Keith W. Pratz is an associate professor of medicine at the Hospital of the University of Pennsylvania. Keith W. Pratz has received honoraria or consultancy fees from AbbVie, Astellas, Boston BioMedical, Jazz Pharmaceuticals, STI Pharmaceuticals, and Celgene; and institutional research funding from AbbVie, Astellas, Agios, and Millennium. Xinglei Chai, Jipan Xie, Lei Yin, and Xiaoyu Nie are employees of Analysis Group, Inc., which has received consulting fees from Genentech, Inc. Melissa Montez, Erica Iantuono, Lisa Downs, and Esprit Ma are employees of Genentech, Inc. and hold stock\/options.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study is a post hoc analysis of previously collected data. No institutional board review was required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The research data are confidential and will not be shared.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Code associated with this research will not be shared.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: all authors; methodology: all authors; formal analysis and investigation: XC, JX, LY, and XN; writing\u2014original draft preparation: XC, JX, LY, XN; writing\u2014review and editing: all authors; funding acquisition: EM; resources: EM; supervision: EM. All authors approved the version of the submitted manuscript and agree to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}